An Active Extension of LAQ/5062 Study. a Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group Study, to Evaluate the Safety, Tolerability and Efficacy of Two Doses (0.3 mg and 0.6 mg) of Laquinimod, Orally Administered in Relapsing Remitting (R-R) Multiple Sclerosis (MS) Subjects (Study LAQ/5063 Active Double-Blind Phase) Followed by an Open Label Phase of Laquinimod 0.6 mg Daily (LAQ/5063 OL)

Trial Profile

An Active Extension of LAQ/5062 Study. a Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group Study, to Evaluate the Safety, Tolerability and Efficacy of Two Doses (0.3 mg and 0.6 mg) of Laquinimod, Orally Administered in Relapsing Remitting (R-R) Multiple Sclerosis (MS) Subjects (Study LAQ/5063 Active Double-Blind Phase) Followed by an Open Label Phase of Laquinimod 0.6 mg Daily (LAQ/5063 OL)

Discontinued
Phase of Trial: Phase II

Latest Information Update: 14 Oct 2017

At a glance

  • Drugs Laquinimod (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions
  • Sponsors Teva Pharmaceutical Industries
  • Most Recent Events

    • 09 Oct 2017 Status changed from active, no longer recruiting to discontinued.
    • 23 Jun 2017 This trial has been discontinued in Hungary.
    • 14 Jun 2017 This trial has been suspended in Czech Republic.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top